U.S. House · 117th Congress · H.R. 6483
Improved Transparency of Foreign Drug Manufacturing Act of 2022
To amend the Federal Food, Drug, and Cosmetic Act to clarify reporting requirements for establishments within a foreign country engaged in the manufacture, preparation, propagation, compounding, or processing of an active pharmaceutical ingredient, and for other purposes.
Follow
Log in to follow this bill and get an email when there’s a new vote (premium).
- Sponsor
- Anna G. EshooD-CA-18
- Introduced
- January 25, 2022, in the House
- Issue areas
- Policy area
- Health (from the Congressional Research Service)
- Full text and actions
- congress.gov
Votes on this bill (0)
Neither the House nor the Senate has held a roll-call vote on this bill.
Cosponsors (0)
No member has cosponsored this bill.